<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TILUDRONATE DISODIUM</span><br/>(til-u'dro-nate)<br/><span class="topboxtradename">Skelid<br/></span><b>Classifications:</b> <span class="classification">regulator, bone metabolism (bisphosphonate)</span><br/><b>Prototype: </b>Etidronate disodium<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>240 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Mechanism of action of this diphosphate is to inhibit osteoclastic activity, which leads to resorption of the bone matrix.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts primarily by inhibiting normal or abnormal bone resorption, thus reducing bone formation. Effectiveness indicated by
         decreasing levels of alkaline phosphatase.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of Paget's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to diphosphonates (e.g., alendronate, etidronate, pamidronate, tiludronate); severe kidney failure (Cl<sub>cr</sub>
</p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hypocalcemia, active UGI problems (e.g., gastritis, dysphagia, ulcer, esophageal disease); CHF. Pregnancy (category C), lactation.
         Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Paget's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg/d with 68 oz of water times 3 mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with 68 oz of plain water 2 h before or after food.</li>
<li>Do not give within 2 h of drugs containing calcium, aspirin, or indomethacin. Give aluminum- or magnesium-containing antacids
            no sooner than 2 h after tiludronate.
         </li>
<li>Store in manufacturer's packaging at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> <span class="speceff-common">Pain,</span> flu-like syndrome, edema. <span class="typehead">CNS:</span> Headache, dizziness, paresthesias. <span class="typehead">CV:</span> Chest pain. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, diarrhea,</span> dyspepsia, vomiting, flatulence. <span class="typehead">Special Senses:</span> Cataract, conjunctivitis, glaucoma. <span class="typehead">Respiratory:</span> Rhinitis, sinusitis, coughing, pharyngitis. <span class="typehead">Skin:</span> Rash. <span class="typehead">Metabolic:</span> Hyperparathyroidism, vitamin D deficiency, <span class="typehead">Musculoskeletal:</span> Arthralgia, arthrosis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Absorption decreased by <span class="classification">calcium</span>, <span class="classification">aluminum</span>- or <span class="classification">magnesium-containing antacids</span>, <b>aspirin.</b> Absorption increased by <b>indomethacin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract. <span class="typehead">Steady-State:</span> 30 d. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 150 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of upper GI dysfunction or ulceration.</li>
<li>Lab tests: Periodic serum calcium and serum phosphate.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not remove tablets from foil strips until time to be taken.</li>
<li>Wait at least 2 h after taking tiludronate to take aluminum- and magnesium-containing antacids.</li>
<li>Consult physician to determine appropriate daily intake of vitamin D and calcium.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>